Key Highlights

  • Shares trading down 2.90% pre-market to $11.39, giving back a portion of Wednesday's after-hours rally
  • Q2 2026 adjusted EPS of $0.20 was in line with consensus, with Revenue of $264.2 million beating estimates by 0.40%
  • Revenue grew 5.1% year-over-year, with system-wide revenue growth of 6% driven by advanced imaging modalities
  • Record free Cash Flow of $23.1 million, a 41% conversion of adjusted EBITDA
  • Narrowed full-year adjusted EBITDA guidance to $235 million to $241 million and reiterated revenue guidance
  • Shares remain down sharply for the year, roughly 37% year-to-date, even after the modest earnings-day bounce

Shares Pull Back From Wednesday's After-Hours Rally

Lumexa Imaging Holdings (NASDAQ:LMRI) shares are pulling back in pre-market trading Thursday, down 2.90% to $11.39, giving back a portion of Wednesday's after-hours rally as investors digest second-quarter results more critically this morning. The company reported adjusted EPS of $0.20, in line with consensus, and revenue of $264.2 million, up 5.1% year-over-year and beating estimates by a narrow 0.40% margin, with record free cash flow of $23.1 million driven by growth in higher-margin advanced imaging modalities, which reached a record 37.4% of total volumes.

Lumexa Imaging Holdings is one of the nation's largest providers of outpatient diagnostic imaging services, operating the second-largest outpatient imaging center footprint in the United States with more than 185 centers across 13 states, including joint venture partnerships with leading health systems. Founded in 2018 by Charlotte Radiology and Private Equity firm Welsh, Carson, Anderson & Stowe and headquartered in Raleigh, North Carolina, the company offers a comprehensive suite of imaging modalities, including MRI, CT, PET scans, X-ray, ultrasound, and mammography, through two operating segments, Outpatient Imaging Centers and Professional Services.

Guidance Narrowed Despite Solid Underlying Trends

Despite reaffirming full-year revenue guidance of $1.045 billion to $1.097 billion and EPS guidance of $0.71 to $0.77, adjusted EBITDA Margin compression to 21.4% from 22.4% a year earlier appears to be weighing on sentiment this morning, even after the stock's initial after-hours enthusiasm faded. Shares remain down sharply for the year, roughly 37% year-to-date, even after the modest earnings-day bounce, with the Balance Sheet strengthened by $69.7 million in cash on hand and net Leverage reduced to 3.6 times from 5.7 times a year ago.

Conclusion

Lumexa Imaging's 2.90% pre-market pullback reflects investors digesting a largely in-line quarter more critically after Wednesday's initial after-hours enthusiasm faded, with margin compression drawing scrutiny despite record free cash flow and continued growth in higher-margin advanced imaging modalities. With shares still down roughly 37% year-to-date and full-year guidance reaffirmed, the stock's next moves will likely hinge on whether margin trends can stabilize as Debt repricing savings begin flowing through in the third quarter.